Cancer was once considered a single disease, but today we are well aware of the many different forms this medical scourge can take, and the many molecular events that can lead to and drive unwanted cell growth. Now, a new partnership between the Michael J. Fox Foundation and 23andMe aims to explore whether Parkinson’s disease...
Anticipation was high for the results of a Phase 3 trial of Axovant’s experimental drug, interpirdine. Sadly, the potential Alzheimer’s disease treatment failed to meet its co-primary endpoints. Patients with mild to moderate Alzheimer’s disease who were treated for 24 weeks with 35 mg interpirdine, along with the existing Alzheimer’s disease drug Aricept, failed to...
Head over to LinkedIn to read an article by our principal consultant Rachel Laing as part of our continuing commentary on Alzheimer’s Disease. https://www.linkedin.com/pulse/alzheimers-disease-diagnostic-dilemma-rachel-laing/
As we wrote in our last post, the ability to accurately diagnose Alzheimer’s disease before a person’s death has been problematic. Experts estimate that a third or more of patients’ cognitive impairment or dementia may be inaccurately diagnosed. As a result, such patients may not benefit from the treatments they do receive or may have...
In July, we attended the Alzheimer’s Association International Conference in London. The big news at the meeting was on the diagnostics front. In the aftermath of the recent string of trial failures, diagnostic tools have become a critical area of focus, in the hopes that patient diagnosis and selection can be improved. Accurately diagnosing...
In early 2011, the National Alzheimer’s Project was formed — a strategic plan aimed at addressing the looming health care crisis posed by the disease and the aging population. Its aim: to coordinate research efforts across the U.S. federal government with the goal of preventing or effectively treating Alzheimer’s Disease by 2025. Since then,...
We recently wrote about the continued, costly failure of Alzheimer’s disease drugs, often occurring in Phase 3 clinical development. Of 244 compounds tested from 2002 to 2012, only one gained approval. Today there are four compounds on the market for Alzheimer’s disease (of six total approved since research began), all aimed at treating symptoms rather...
Alzheimer’s Disease: Part One – Another one bites the dust, but a possible glimmer of hope on the horizon On February 14, Merck halted the Phase 3 trial of its Alzheimer’s disease drug candidate, verubecestat, after independent analysis showed that the drug had “virtually no chance of working.” This late stage failure was just the...